Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BAFF/TNFSF13B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BAFF (TNFSF13B) Recombinant Protein Trimeric form, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View BAFF Products |
| Receptor | BAFF-R (TNFRSF13C) ECD-Fc Fusion Protein For competitive binding and SPR assays. |
View TNFRSF13C Products |
| Receptor | TACI (TNFRSF13B) ECD-Fc Fusion Protein BAFF/APRIL shared receptor for selectivity testing. |
View TNFRSF13B Products |
| Receptor | BCMA (TNFRSF17) ECD-Fc Fusion Protein For plasma cell targeting validation. |
View TNFRSF17 Products |
| Gene Delivery | BAFF-R Lentivirus Particles For stable cell line construction (Flow Cytometry/Reporter assays). |
View TNFRSF13C Products |
| Benchmark Ab | Anti-BAFF (Belimumab Sequence) Recombinant positive control, Sequence-verified. |
View BAFF Products |
| Competitor Ligand | APRIL (TNFSF13) Recombinant Protein For selectivity counter-screening vs BAFF. |
View TNFSF13 Products |
| Validator | BAFF siRNA Set For knockdown verification and specificity controls. |
View BAFF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimerization-dependent activity | Native trimeric BAFF protein maintained via HEK293 expression; Theoretical MW verified; Oligomeric state confirmed |
| APRIL selectivity screening | BAFF vs APRIL homolog panel proteins with >95% purity, strictly verified by mass spec |
| Receptor selectivity (BAFF-R vs TACI/BCMA) | Individual receptor ECD-Fc proteins (Human/Mouse/Cyno) for competitive binding assays |
| Cross-species cyno/mouse eval | Ortholog proteins available with sequence identity verified, Endotoxin controlled |
| False Positives | Validated siRNA included for target-specificity confirmation |
Live BAFF R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The BAFF therapeutic landscape is evolving beyond monospecific blockade toward dual-pathway inhibition. Belimumab (anti-BAFF, GSK) established the standard of care in Systemic Lupus Erythematosus (SLE), while next-generation candidates such as Atacicept (Sanofi/Merck) and Telitacicept (RemeGen) target both BAFF and APRIL to achieve deeper B-cell suppression. The pipeline also includes Tabalumab (Eli Lilly) and Blisibimod (Anthera, a peptibody), demonstrating diverse modalities. As first-generation therapies validate the target, the race is intensifying around receptor-Fc fusion proteins and bispecific molecules, striving to modulate B-cell survival without compromising protective immunity. Key emerging indications include IgA Nephropathy, Sjögren's syndrome, and multiple myeloma (via BCMA targeting).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-BAFF mAb | GSK (Belimumab), Eli Lilly (Tabalumab) | SLE, Sjögren's Syndrome, RA | Receptor selectivity assay (Need BAFF-R vs TACI/BCMA ECD-Fc) |
| TACI-Fc Fusion | Sanofi (Atacicept), RemeGen (Telitacicept), Vera Therapeutics | IgA Nephropathy, SLE, MS | Dual ligand competition (Need BAFF + APRIL protein panel) |
| Anti-BCMA ADC | GSK, Bristol Myers Squibb | Multiple Myeloma | Cell-based internalization (Need BAFF-R Lentivirus stable lines) |
| Peptibody | Anthera (Blisibimod) | IgA Nephropathy | In vitro stability (Need sequence-verified standard antigens) |
| Bispecific (e.g., BAFF x IL-17) | Multiple Biopharmas | Complex Autoimmune | Cross-species binding (Need Cyno/Mouse ortholog proteins) |